I'm LongbridgeAI, I can summarize articles.Vaxcyte released its September investor presentation detailing the VAX-31 pneumococcal conjugate vaccine strategy. Enrollment is complete in three Phase 3 trials, with OPUS-1 data expected by October 2026 and others in early 2027. The company holds approximately $2.5 billion in cash as of June 2026. The presentation also highlights earlier-stage programs for Group A strep and Shigella.
- Vaxcyte released an investor presentation outlining its pneumococcal conjugate vaccine strategy, led by 31-valent candidate VAX-31. * Enrollment completed in three Phase 3 adult trials for VAX-31, including OPUS-1, a pivotal noninferiority study. * Topline OPUS-1 adult data expected by end-October 2026; OPUS-2 and OPUS-3 readouts targeted in the first half of 2027. * Cash, cash equivalents, investments totaled about $2.5 billion as of June 30, 2026. * Presentation also highlights earlier-stage programs in Group A strep and Shigella, leveraging its cell-free protein synthesis platform. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief on September 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here